---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-006012"
form_type: "8-K"
ticker: "ALLR"
cik: "0001860657"
company_name: "Allarity Therapeutics, Inc."
filed_at: "2025-03-04T23:59:59+00:00"
generated_at: "2026-05-25T15:37:55.632839+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Allarity Therapeutics authorizes $5M share repurchase program through Feb 2026

## Summary
- Board authorized repurchase of up to $5M of common stock; program runs through Feb 28, 2026.
- CEO Thomas Jensen cites confidence in stenoparib’s clinical potential and long-term vision.
- Company says sufficient cash position maintains runway into 2026, unaffected by buyback.
- Repurchases discretionary; may be made via open market or other methods under Rule 10b-18.
- Allarity is a Phase 2 clinical-stage biotech developing dual PARP/Wnt inhibitor stenoparib.

## SEC filing metadata
- accession: 0001437749-25-006012
- form_type: 8-K
- ticker: ALLR
- cik: 0001860657
- company_name: Allarity Therapeutics, Inc.
- filed_at: 2025-03-04T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1860657/000143774925006012/0001437749-25-006012-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1860657/000143774925006012/allr20250303_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-006012
- JSON: https://secwatch.observer/filing/0001437749-25-006012.json
- Plain text: https://secwatch.observer/filing/0001437749-25-006012.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.